MedAdvisor Limited
MedAdvisor Limited (MDR.AX) Stock Competitors & Peer Comparison
See (MDR.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MDR.AX | A$0.02 | +0.00% | 14M | -0.20 | -A$0.11 | N/A |
| PME.AX | A$118.84 | -4.14% | 12.4B | 53.05 | A$2.24 | +0.52% |
| CGS.AX | A$2.13 | -1.84% | 364.2M | 23.67 | A$0.09 | +0.94% |
| AYA.AX | A$3.13 | -5.44% | 356.2M | -18.41 | -A$0.17 | N/A |
| VHT.AX | A$1.15 | +0.44% | 291.3M | -28.63 | -A$0.04 | N/A |
| ALC.AX | A$0.10 | +0.00% | 134.3M | -10.00 | -A$0.01 | N/A |
| ONE.AX | A$0.18 | -2.78% | 134.3M | -5.83 | -A$0.03 | N/A |
| M7T.AX | A$0.32 | -4.55% | 74M | -7.87 | -A$0.04 | N/A |
| SHG.AX | A$0.23 | +2.27% | 71M | -11.25 | -A$0.02 | N/A |
| PHX.AX | A$0.11 | +0.00% | 69.2M | N/A | N/A | N/A |
Stock Comparison
MDR.AX vs PME.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, PME.AX has a market cap of 12.4B. Regarding current trading prices, MDR.AX is priced at A$0.02, while PME.AX trades at A$118.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas PME.AX's P/E ratio is 53.05. In terms of profitability, MDR.AX's ROE is -2.31%, compared to PME.AX's ROE of +0.73%. Regarding short-term risk, MDR.AX is more volatile compared to PME.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check PME.AX's competition here
MDR.AX vs CGS.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, CGS.AX has a market cap of 364.2M. Regarding current trading prices, MDR.AX is priced at A$0.02, while CGS.AX trades at A$2.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas CGS.AX's P/E ratio is 23.67. In terms of profitability, MDR.AX's ROE is -2.31%, compared to CGS.AX's ROE of +0.29%. Regarding short-term risk, MDR.AX is more volatile compared to CGS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check CGS.AX's competition here
MDR.AX vs AYA.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, AYA.AX has a market cap of 356.2M. Regarding current trading prices, MDR.AX is priced at A$0.02, while AYA.AX trades at A$3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas AYA.AX's P/E ratio is -18.41. In terms of profitability, MDR.AX's ROE is -2.31%, compared to AYA.AX's ROE of -0.36%. Regarding short-term risk, MDR.AX is less volatile compared to AYA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MDR.AX.Check AYA.AX's competition here
MDR.AX vs VHT.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, VHT.AX has a market cap of 291.3M. Regarding current trading prices, MDR.AX is priced at A$0.02, while VHT.AX trades at A$1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas VHT.AX's P/E ratio is -28.63. In terms of profitability, MDR.AX's ROE is -2.31%, compared to VHT.AX's ROE of -0.18%. Regarding short-term risk, MDR.AX is more volatile compared to VHT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check VHT.AX's competition here
MDR.AX vs ALC.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, ALC.AX has a market cap of 134.3M. Regarding current trading prices, MDR.AX is priced at A$0.02, while ALC.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas ALC.AX's P/E ratio is -10.00. In terms of profitability, MDR.AX's ROE is -2.31%, compared to ALC.AX's ROE of +0.04%. Regarding short-term risk, MDR.AX is more volatile compared to ALC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check ALC.AX's competition here
MDR.AX vs ONE.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, ONE.AX has a market cap of 134.3M. Regarding current trading prices, MDR.AX is priced at A$0.02, while ONE.AX trades at A$0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas ONE.AX's P/E ratio is -5.83. In terms of profitability, MDR.AX's ROE is -2.31%, compared to ONE.AX's ROE of -2.27%. Regarding short-term risk, MDR.AX is more volatile compared to ONE.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check ONE.AX's competition here
MDR.AX vs M7T.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, M7T.AX has a market cap of 74M. Regarding current trading prices, MDR.AX is priced at A$0.02, while M7T.AX trades at A$0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas M7T.AX's P/E ratio is -7.87. In terms of profitability, MDR.AX's ROE is -2.31%, compared to M7T.AX's ROE of -0.24%. Regarding short-term risk, MDR.AX is more volatile compared to M7T.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check M7T.AX's competition here
MDR.AX vs SHG.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, SHG.AX has a market cap of 71M. Regarding current trading prices, MDR.AX is priced at A$0.02, while SHG.AX trades at A$0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas SHG.AX's P/E ratio is -11.25. In terms of profitability, MDR.AX's ROE is -2.31%, compared to SHG.AX's ROE of -0.60%. Regarding short-term risk, MDR.AX is more volatile compared to SHG.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check SHG.AX's competition here
MDR.AX vs PHX.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, PHX.AX has a market cap of 69.2M. Regarding current trading prices, MDR.AX is priced at A$0.02, while PHX.AX trades at A$0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas PHX.AX's P/E ratio is N/A. In terms of profitability, MDR.AX's ROE is -2.31%, compared to PHX.AX's ROE of -0.02%. Regarding short-term risk, MDR.AX is more volatile compared to PHX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check PHX.AX's competition here
MDR.AX vs DOC.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, DOC.AX has a market cap of 49.5M. Regarding current trading prices, MDR.AX is priced at A$0.02, while DOC.AX trades at A$0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas DOC.AX's P/E ratio is 13.50. In terms of profitability, MDR.AX's ROE is -2.31%, compared to DOC.AX's ROE of +2.51%. Regarding short-term risk, MDR.AX is more volatile compared to DOC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check DOC.AX's competition here
MDR.AX vs BMT.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, BMT.AX has a market cap of 42.9M. Regarding current trading prices, MDR.AX is priced at A$0.02, while BMT.AX trades at A$0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas BMT.AX's P/E ratio is -7.37. In terms of profitability, MDR.AX's ROE is -2.31%, compared to BMT.AX's ROE of -0.14%. Regarding short-term risk, MDR.AX is more volatile compared to BMT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check BMT.AX's competition here
MDR.AX vs VHL.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, VHL.AX has a market cap of 38.8M. Regarding current trading prices, MDR.AX is priced at A$0.02, while VHL.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas VHL.AX's P/E ratio is -2.00. In terms of profitability, MDR.AX's ROE is -2.31%, compared to VHL.AX's ROE of -4.12%. Regarding short-term risk, MDR.AX is more volatile compared to VHL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check VHL.AX's competition here
MDR.AX vs PCK.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, PCK.AX has a market cap of 33.4M. Regarding current trading prices, MDR.AX is priced at A$0.02, while PCK.AX trades at A$0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas PCK.AX's P/E ratio is -3.20. In terms of profitability, MDR.AX's ROE is -2.31%, compared to PCK.AX's ROE of -10.10%. Regarding short-term risk, MDR.AX is more volatile compared to PCK.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check PCK.AX's competition here
MDR.AX vs EMD.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, EMD.AX has a market cap of 26.9M. Regarding current trading prices, MDR.AX is priced at A$0.02, while EMD.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas EMD.AX's P/E ratio is -4.70. In terms of profitability, MDR.AX's ROE is -2.31%, compared to EMD.AX's ROE of -0.52%. Regarding short-term risk, MDR.AX is less volatile compared to EMD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MDR.AX.Check EMD.AX's competition here
MDR.AX vs COO.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, COO.AX has a market cap of 26.3M. Regarding current trading prices, MDR.AX is priced at A$0.02, while COO.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas COO.AX's P/E ratio is N/A. In terms of profitability, MDR.AX's ROE is -2.31%, compared to COO.AX's ROE of -0.05%. Regarding short-term risk, MDR.AX is more volatile compared to COO.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check COO.AX's competition here
MDR.AX vs IME.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, IME.AX has a market cap of 21.1M. Regarding current trading prices, MDR.AX is priced at A$0.02, while IME.AX trades at A$0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas IME.AX's P/E ratio is -6.50. In terms of profitability, MDR.AX's ROE is -2.31%, compared to IME.AX's ROE of -0.19%. Regarding short-term risk, MDR.AX is more volatile compared to IME.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check IME.AX's competition here
MDR.AX vs TRI.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, TRI.AX has a market cap of 20.8M. Regarding current trading prices, MDR.AX is priced at A$0.02, while TRI.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas TRI.AX's P/E ratio is N/A. In terms of profitability, MDR.AX's ROE is -2.31%, compared to TRI.AX's ROE of -0.08%. Regarding short-term risk, MDR.AX is more volatile compared to TRI.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check TRI.AX's competition here
MDR.AX vs RHT.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, RHT.AX has a market cap of 20M. Regarding current trading prices, MDR.AX is priced at A$0.02, while RHT.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas RHT.AX's P/E ratio is N/A. In terms of profitability, MDR.AX's ROE is -2.31%, compared to RHT.AX's ROE of +0.08%. Regarding short-term risk, MDR.AX is more volatile compared to RHT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check RHT.AX's competition here
MDR.AX vs 1ST.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, 1ST.AX has a market cap of 15.6M. Regarding current trading prices, MDR.AX is priced at A$0.02, while 1ST.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas 1ST.AX's P/E ratio is -1.10. In terms of profitability, MDR.AX's ROE is -2.31%, compared to 1ST.AX's ROE of +0.69%. Regarding short-term risk, MDR.AX is more volatile compared to 1ST.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check 1ST.AX's competition here
MDR.AX vs AHE.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, AHE.AX has a market cap of 12.1M. Regarding current trading prices, MDR.AX is priced at A$0.02, while AHE.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas AHE.AX's P/E ratio is -0.19. In terms of profitability, MDR.AX's ROE is -2.31%, compared to AHE.AX's ROE of -1.37%. Regarding short-term risk, MDR.AX is more volatile compared to AHE.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check AHE.AX's competition here
MDR.AX vs ICR.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, ICR.AX has a market cap of 11.8M. Regarding current trading prices, MDR.AX is priced at A$0.02, while ICR.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas ICR.AX's P/E ratio is -2.50. In terms of profitability, MDR.AX's ROE is -2.31%, compared to ICR.AX's ROE of +5.38%. Regarding short-term risk, MDR.AX is less volatile compared to ICR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MDR.AX.Check ICR.AX's competition here
MDR.AX vs PKY.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, PKY.AX has a market cap of 7.8M. Regarding current trading prices, MDR.AX is priced at A$0.02, while PKY.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas PKY.AX's P/E ratio is -2.20. In terms of profitability, MDR.AX's ROE is -2.31%, compared to PKY.AX's ROE of -11.22%. Regarding short-term risk, MDR.AX is more volatile compared to PKY.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check PKY.AX's competition here
MDR.AX vs ENL.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, ENL.AX has a market cap of 7.5M. Regarding current trading prices, MDR.AX is priced at A$0.02, while ENL.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas ENL.AX's P/E ratio is -0.30. In terms of profitability, MDR.AX's ROE is -2.31%, compared to ENL.AX's ROE of -1.39%. Regarding short-term risk, MDR.AX is more volatile compared to ENL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check ENL.AX's competition here
MDR.AX vs HIQ.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, HIQ.AX has a market cap of 6.4M. Regarding current trading prices, MDR.AX is priced at A$0.02, while HIQ.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas HIQ.AX's P/E ratio is -1.30. In terms of profitability, MDR.AX's ROE is -2.31%, compared to HIQ.AX's ROE of +1.53%. Regarding short-term risk, MDR.AX is more volatile compared to HIQ.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check HIQ.AX's competition here
MDR.AX vs VFX.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, VFX.AX has a market cap of 6.1M. Regarding current trading prices, MDR.AX is priced at A$0.02, while VFX.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas VFX.AX's P/E ratio is -3.55. In terms of profitability, MDR.AX's ROE is -2.31%, compared to VFX.AX's ROE of +2.45%. Regarding short-term risk, MDR.AX is more volatile compared to VFX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check VFX.AX's competition here
MDR.AX vs OPL.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, OPL.AX has a market cap of 5.4M. Regarding current trading prices, MDR.AX is priced at A$0.02, while OPL.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas OPL.AX's P/E ratio is -2.20. In terms of profitability, MDR.AX's ROE is -2.31%, compared to OPL.AX's ROE of +12.68%. Regarding short-term risk, MDR.AX is more volatile compared to OPL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check OPL.AX's competition here
MDR.AX vs MEB.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, MEB.AX has a market cap of 4.5M. Regarding current trading prices, MDR.AX is priced at A$0.02, while MEB.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas MEB.AX's P/E ratio is -0.10. In terms of profitability, MDR.AX's ROE is -2.31%, compared to MEB.AX's ROE of -0.15%. Regarding short-term risk, MDR.AX is less volatile compared to MEB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MDR.AX.Check MEB.AX's competition here
MDR.AX vs GLH.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, GLH.AX has a market cap of 3.9M. Regarding current trading prices, MDR.AX is priced at A$0.02, while GLH.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas GLH.AX's P/E ratio is -6.70. In terms of profitability, MDR.AX's ROE is -2.31%, compared to GLH.AX's ROE of +0.20%. Regarding short-term risk, MDR.AX is more volatile compared to GLH.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check GLH.AX's competition here
MDR.AX vs TD1.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, TD1.AX has a market cap of 2.1M. Regarding current trading prices, MDR.AX is priced at A$0.02, while TD1.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas TD1.AX's P/E ratio is -2.20. In terms of profitability, MDR.AX's ROE is -2.31%, compared to TD1.AX's ROE of -0.42%. Regarding short-term risk, MDR.AX is more volatile compared to TD1.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check TD1.AX's competition here
MDR.AX vs CTQ.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, CTQ.AX has a market cap of 1.7M. Regarding current trading prices, MDR.AX is priced at A$0.02, while CTQ.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas CTQ.AX's P/E ratio is -0.70. In terms of profitability, MDR.AX's ROE is -2.31%, compared to CTQ.AX's ROE of -0.14%. Regarding short-term risk, MDR.AX is more volatile compared to CTQ.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check CTQ.AX's competition here
MDR.AX vs OAK.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, OAK.AX has a market cap of 1.7M. Regarding current trading prices, MDR.AX is priced at A$0.02, while OAK.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas OAK.AX's P/E ratio is 6.30. In terms of profitability, MDR.AX's ROE is -2.31%, compared to OAK.AX's ROE of +0.17%. Regarding short-term risk, MDR.AX is more volatile compared to OAK.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check OAK.AX's competition here
MDR.AX vs JTL.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, JTL.AX has a market cap of 281.3K. Regarding current trading prices, MDR.AX is priced at A$0.02, while JTL.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas JTL.AX's P/E ratio is -0.10. In terms of profitability, MDR.AX's ROE is -2.31%, compared to JTL.AX's ROE of +0.60%. Regarding short-term risk, MDR.AX is more volatile compared to JTL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check JTL.AX's competition here
MDR.AX vs TTB.AX Comparison April 2026
MDR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDR.AX stands at 14M. In comparison, TTB.AX has a market cap of 267.4K. Regarding current trading prices, MDR.AX is priced at A$0.02, while TTB.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDR.AX currently has a P/E ratio of -0.20, whereas TTB.AX's P/E ratio is -0.02. In terms of profitability, MDR.AX's ROE is -2.31%, compared to TTB.AX's ROE of -1.05%. Regarding short-term risk, MDR.AX is more volatile compared to TTB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MDR.AX.Check TTB.AX's competition here